Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “Human Immunodeficiency Virus-Type 1”

Showing 20 of 0 results

Early research (Phase 1)Study completedNCT05197075
What this trial is testing

Assess the Acceptability of the Darunavir/Cobicistat (DRV/COBI) Fixed-dose Combination (FDC) Tablet in Human Immunodeficiency Virus (HIV)-1 Infected Children

Who this might be right for
Human Immunodeficiency Virus (HIV)
Janssen Research & Development, LLC 15
Not applicableWithdrawnNCT00165919
What this trial is testing

Immune Response to Hepatitis C Virus

Who this might be right for
Hepatitis CHIV Infections
Emory University
Large-scale testing (Phase 3)Study completedNCT00480792
What this trial is testing

Trial Comparing Three Strategies of Vaccination Against the Virus of Hepatitis B in HIV Infected Patients

Who this might be right for
HIV Infections
ANRS, Emerging Infectious Diseases 437
Not applicableStudy completedNCT00002404
What this trial is testing

The Effect of Valacyclovir on the Detection of HIV From Genital Herpes Lesions in HIV-Infected Patients

Who this might be right for
Herpes SimplexHIV Infections
Glaxo Wellcome 30
Post-approval studies (Phase 4)Study completedNCT04388904
What this trial is testing

Rapid Reinitiation of a Single Tablet Antiretroviral Therapy Using Symtuza® in HIV-1 Infected Treatment-Experienced Patients Off Therapy. (ReSTART)

Who this might be right for
HIV-1-infection
The Crofoot Research Center, Inc. 75
Not applicableStudy completedNCT00005278
What this trial is testing

Retrovirus Epidemiology Donor Study I (REDS I)

Who this might be right for
Acquired Immunodeficiency SyndromeBlood DonorsBlood Transfusion+6 more
National Heart, Lung, and Blood Institute (NHLBI)
Early research (Phase 1)Looking for participantsNCT03729752
What this trial is testing

PET Imaging of Radiolabeled Anti-HIV-1 Envelope Monoclonal Antibody (VRC01)

Who this might be right for
HIV-1-infection
University of California, San Francisco 30
Testing effectiveness (Phase 2)UnknownNCT00622232
What this trial is testing

A Rollover Study for Subjects Who Completed Participation in the VRX496-USA-05-002 Trial

Who this might be right for
HIV Infections
VIRxSYS Corporation 40
Early research (Phase 1)Study completedNCT00001021
What this trial is testing

A Phase I Multicenter Study of the Safety and Immunogenicity of MN rgp120/HIV-1 Vaccine Given Either Alone or in Combination With IIIB rgp120/HIV-1 Vaccine in Healthy Adult Subjects (NOTE: Original Study Extended ONLY for Patients Previously Enrolled on VEU 009)

Who this might be right for
HIV Infections
National Institute of Allergy and Infectious Diseases (NIAID) 57
Large-scale testing (Phase 3)Active Not RecruitingNCT05631093
What this trial is testing

A Switch to Doravirine/Islatravir (DOR/ISL) in Participants With Human Immunodeficiency Virus Type 1 (HIV-1) Who Are Virologically Suppressed on Antiretroviral Therapy (ART) (MK-8591A-051)

Who this might be right for
HIV-1 Infection
Merck Sharp & Dohme LLC 553
Early research (Phase 1)Study completedNCT00119873
What this trial is testing

Safety of and Immune Response to an Experimental HIV Vaccine (VRC-HIVADV014-00-VP) in HIV Uninfected Adults

Who this might be right for
HIV Infections
National Institute of Allergy and Infectious Diseases (NIAID) 48
Early research (Phase 1)Study completedNCT01575405
What this trial is testing

Compare Three Different Formulations of Tenofovir 1% Gel When Administered Rectally

Who this might be right for
HIV Prevention
Ian McGowan 13
Testing effectiveness (Phase 2)Study completedNCT00001031
What this trial is testing

A Phase II Clinical Trial to Evaluate the Immunogenicity and Reactogenicity of the Recombinant HIV-1 Envelope Vaccines SF-2 rgp120 (CHO) [Chiron Vaccines] in MF59 Adjuvant and MN rgp120/HIV-1 [VaxGen] in Alum Adjuvant in Healthy Adults

Who this might be right for
HIV Infections
National Institute of Allergy and Infectious Diseases (NIAID) 296
Not applicableStudy completedNCT06368453
What this trial is testing

Evaluate the Performance, Usability, and Result Interpretation of INSTI® HIV Self-Test

Who this might be right for
Human Immunodeficiency Virus I InfectionHuman Immunodeficiency Virus II Infection
bioLytical Laboratories 1,728
Testing effectiveness (Phase 2)Study completedNCT01549119
What this trial is testing

Phase I/IIa Dose-escalation Clinical Study of VAC-3S

Who this might be right for
HIV-1 Infection
InnaVirVax 33
Testing effectiveness (Phase 2)Study completedNCT03525730
What this trial is testing

LRAs United as a Novel Anti-HIV Strategy.

Who this might be right for
HIV-1-infection
Erasmus Medical Center 28
Post-approval studies (Phase 4)Study completedNCT04296695
What this trial is testing

Biktarvy in Treatment-Naïve Late Presenters With HIV-1 Infection

Who this might be right for
HIV-1-infection
Peking Union Medical College Hospital 202
Large-scale testing (Phase 3)Study completedNCT01386294
What this trial is testing

Safety and Effectiveness of Tenofovir Gel in the Prevention of Human Immunodeficiency Virus (HIV-1) Infection in Women and the Effects of Tenofovir Gel on the Incidence of Herpes Simplex Virus (HSV-2) Infection

Who this might be right for
HIV Prevention
CONRAD 2,059
Post-approval studies (Phase 4)Study completedNCT03683524
What this trial is testing

EFFICACY AND SAFETY OF A SIMPLIFICATION STRATEGY BASED ON DOLUTEGRAVIR AND DARUNAVIR / COBICISTAT VS OPTIMIZED TREATMENT IN SUPPRESSED HIV-1-INFECTED PATIENTS CARRYING ARCHIVED MULTIDRUG RESISTANCE MUTATIONS

Who this might be right for
HIV-1 Infection
Fundación FLS de Lucha Contra el Sida, las Enfermedades Infecciosas y la Promoción de la Salud y la Ciencia 96
Testing effectiveness (Phase 2)WithdrawnNCT03074786
What this trial is testing

Reversing the Epidemic in Africa With Choices in HIV Prevention (REACH)

Who this might be right for
HIV-1-infection
International Partnership for Microbicides, Inc.
Next Page

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation